## The Global HIV/AIDS Epidemic, risk factors for transmission and Global response

#### Training Course in Sexual and Reproductive Health Research 2014

*Txema Calleja HIV Dept.* July 2014

Data based in UNAIDS and WHO Global reports



Principles and Practice of Sexually Transmitted Diseases Prevention and Care

## Outline

- Basic concepts
- HIV transmission factors
- HIV surveillance and estimates

### HIV Prevention:

- Male circumcision
- Treatment as Prevention
- HIV treatment

### Conclusions

#### Basic concepts





# **HIV epidemiology**





4 Principles and Practice of Sexually Transmitted Diseases Prevention and Care

## **HIV** incidence

- Incidence: Number of new HIV infections (number of people newly infected with HIV)
  - usually per year
- Incidence rate: Rate of new HIV infections
  - usually per 100 person-years
  - usually per 100 susceptible persons [leaving out those already infected]



# **HIV epidemiology**





## **HIV prevalence**

- Prevalence: Number of people with HIV infection
- or "Number of people living with HIV PLHIV" usually per year
- Prevalence rate or Prevalence (%): Percentage of PLHIV per population

usually per 100 population



# **HIV epidemiology**







## **AIDS-related mortality**

- Number of AIDS-related deaths usually per year
- AIDS-specific mortality rate: usually per year per 100, 1,000 or 100,000 population
- Proportion of AIDS deaths: of all deaths, the percentage that are due to AIDS



## The natural course of incidence and prevalence of a local HIV epidemic over time



Principles and Practice of Sexually Transmitted Diseases Prevention and Care



#### Dinamics of epiemic dissemination: Basic rate of reproduction of and STI (R<sub>0</sub>)





# What we know about HIV transmission and risk factors ?



### **The Proximate-Determinants Framework**



Proximate-determinants conceptual framework for factors affecting the risk of sexual transmission of HIV. ARVs, antiretrovirals; STI, Figure 1. sexually transmitted infection.

J. Ties Boermaa and Sharon S. Weir Integrating Demographic and Epidemiological Approaches to Research on HIV/AIDS: The Proximate-Determinants Framework Framework for HIV/AIDS Research • JID 2005:191 (Suppl 1) So World Health 14 Principles and Practice of Sexually Transmitted Diseases Prevention and Care



# The new paradigm: HIV transmission does not occur at random, but is concentrated where risks come together

H Gayle MIP presentation





## **Classification of epidemics - classic**

#### Low level

•Principle: Although HIV infection may have existed for many years, it has never spread to significant levels in any sub-population.

•Infection is largely confined to individuals with higher risk behaviour: e.g. sex workers, drug injectors, MSM. This suggests that networks of risk are rather diffuse (low levels of partner exchange or sharing of drug injecting equipment), or a very recent introduction of the virus.

•Numerical proxy: HIV prevalence has not consistently exceeded five percent in any defined sub-population.



## **Classification of epidemics - classic**

#### Concentrated

•Principle: HIV has spread rapidly in a defined sub-population, but is not well-established in the general population.

•This suggests active networks of risk within the sub-population. The future course of the epidemic is determined by the frequency and nature of links between highly infected sub-populations and the general population.

•Numerical proxy: HIV prevalence consistently over five percent in at least one defined sub-population. HIV prevalence below one percent in pregnant women in urban areas



## **Classification of epidemics - classic**

#### Generalised

•Principle: In generalised epidemics, HIV is firmly established in the general population.

•Although sub-populations at high risk may continue to contribute disproportionately to the spread of HIV, sexual networking in the general population is sufficient to sustain an epidemic independent of sub-populations at higher risk of infection.

•Numerical proxy: HIV prevalence consistently over one percent in pregnant women nation-wide.

18



## **Other classifications**

- UNAIDS: Low-level, Concentrated, Generalized, Hyperendemic
- Wilson & Halperin (Lancet 2008): "concentrated", "generalised", "potentially mixed"
- Mishra (PLoSOne 2012): "concentrated local", "concentrated nonlocal", "concentrated local and non-local", "generalizing", "mixed"
- .... and several others



### **Epidemiology definitions: other considerations**

- Statistics often presented separately for adults and children (also because major modes of transmission are different)
- Mortality among PLHIV can be due to AIDS or to other causes (accident, flu, etc.)



#### Incidence is not constant









# New infections by type of exposure

Source: Pisani et al. BMJ 2003; 326: 1384-7

Fig 1 Distribution of new HIV infections by type of exposure in selected countries, 1998-2002. Data on behaviour and HIV prevalence drawn from references 7-17

ention and Care



#### **Concentrated epidemics all follow similar patterns...**





### Thailand: changes of modes of tranmission





#### Number of infections per year and mode of transnmission, Cambodia, 1988-2004



■ Male clients Sex workers Wife from husban, Husband from wife Mother to child Source: Peerapatanapokin and Brown, using Asia Epidemic Model





Sexual and drug taking networks are frequently complex and intertwined. A "one size fits all" approach to addressing behavioral risk rarely addresses local realities.





### Where we are with the HIV epidemic: HIV surveillance and estimates





#### **Overview for HIV Estimates**









2010



-----

#### **Global prevalence of HIV, 2010**









### **People living with HIV**







#### **New HIV infections and AIDS-related deaths**





#### Global HIV trends, 1990 to 2009

#### All Children estimates have larger ranges



Number of people living with HIV



Number of children living with HIV



Dotted lines represent ranges, solid lines represent the best estimate.





		Adults and children living with HIV	Adults and children newly infected with HIV	Adult prevalence (%)	Adult and child deaths due to AIDS	Young people (15– 24) prevalence (%)	
						Male	Female
SUB-SAHARAN AFRICA	2010	<b>22.9 million</b> [21.6-24.1 million]	1.9 million [1.7-2.1 million]	<b>5.0</b> [4.7–5.2]	1.2 million [1.1-1.4 million]	<b>1.4</b> [1.1–1.8]	<b>3.3</b> [2.7–4.2]
	2001	<b>20.5 million</b> [19.1-22.2 million]	<b>2.2 million</b> [2.1-2.4 million]	<b>5.9</b> [5.6-6.4]	<b>1.4 million</b> [1.3–1.6 million]	<b>2.0</b> [1.6–2.7]	<b>5.2</b> [4.3-6.8]
MIDDLE EAST AND NORTH AFRICA	2010	<b>470 000</b> [350 000-570 000]	<b>59 000</b> [40 000–73 000]	<b>0.2</b> [0.2–0.3]	<b>35 000</b> [25 000-42 000]	<b>0.1</b> [0.1–0.2]	<b>0.2</b> [0.1–0.2]
	2001	<b>320 000</b> [190 000-450 000]	<b>43 000</b> [31 000–57 000]	<b>0.2</b> [0.1–0.3]	<b>22 000</b> [9700-38 000]	<b>0.1</b> [0.1–0.2]	<b>0.1</b> [0.1–0.2]



		Adults and children living with HIV	Adults and children newly infected with HIV	Adult prevalence (%)	Adult and child deaths due to AIDS	Young people (15– 24) prevalence (%)	
						Wate	remaie
SOUTH AND SOUTH-EAST ASIA	2010	4.0 million [3.6-4.5 million]	<b>270 000</b> [230 000-340 000]	<b>0.3</b> [0.3–0.3]	<b>250 000</b> [210 000-280 000]	<b>0.1</b> [0.1–0.2]	<b>0.1</b> [0.1–0.1]
	2001	<b>3.8 million</b> [3.4-4.2 million]	<b>380 000</b> [340 000-420 000]	<b>0.3</b> [0.3–0.4]	<b>230 000</b> [200 000-280 000]	<b>0.2</b> [0.2–0.2]	<b>0.2</b> [0.2–0.2]
EAST ASIA	2010	<b>790 000</b> [580 000–1.1 million]	<b>88 000</b> [48 000-160 000]	<b>0.1</b> [0.1-0.1]	<b>56 000</b> [40 000-76 000]	<b>&lt;0.1</b> [<0.1-<0.1	<b>&lt;0.1</b>
	2001	<b>380 000</b> [280 000-530 000]	<b>74 000</b> [54 000-100 000]	<b>&lt;0.1</b> [<0.1-0.1]	<b>24 000</b> [16 000-45 000]	<b>&lt;0.1</b> [<0.1-<0.1	<b>&lt;0.1</b>



		Adults and children living with HIV	Adults and children newly infected with HIV	Adult prevalence (%)	Adult and child deaths due to AIDS	Young people (15– 24) prevalence (%)	
						Male	Female
OCEANIA	2010	<b>54 000</b> [48 000-62 000]	<b>3300</b> [2400-4200]	<b>0.3</b> [0.2–0.3]	<b>1600</b> [1200-2000]	<b>0.1</b> [0.1–0.1]	<b>0.2</b> [0.1–0.2]
	2001	<b>41 000</b> [34 000–50 000]	<b>4000</b> [3300-4600]	<b>0.2</b> [0.2-0.3]	<b>1800</b> [1300-2900]	<b>0.1</b> [0.1–0.2]	<b>0.2</b> [0.2–0.3]
LATIN AMERICA	2010	1.5 million [1.2–1.7 million]	<b>100 000</b> [73 000–140 000]	<b>0.4</b> [0.30.5]	<b>67 000</b> [45 000-92 000]	<b>0.2</b> [0.1–0.4]	<b>0.2</b> [0.1–0.2]
	2001	<b>1.3 million</b> [1.0-1.7 million]	<b>99 000</b> [75 000–130 000]	<b>0.4</b> [0.3–0.5]	<b>83 000</b> [50 000-130 000]	<b>0.2</b> [0.1–0.6]	<b>0.1</b> [0.1–0.2]

		Adults and children living with HIV	Adults and children newly infected with HIV	Adult prevalence (%)	Adult and child deaths due to AIDS	Young people (15– 24) prevalence (%) Male Female	
CARIBBEAN	2010	<b>200 000</b> [170 000-220 000]	<b>12 000</b> [9400-17 000]	<b>0.9</b> [0.8–1.0]	<b>9000</b> [6900–12 000]	<b>0.2</b> [0.2–0.5]	<b>0.5</b> [0.3–0.7]
	2001	<b>210 000</b> [170 000–240 000]	<b>19 000</b> [16 000–22 000]	<b>1.0</b> [0.9–1.2]	<b>18 000</b> [14 000-22 000]	<b>0.4</b> [0.2–0.8]	<b>0.8</b> [0.6–1.1]
EASTERN EUROPE AND	2010	1.5 million [1.3-1.7 million]	<b>160 000</b> [110 000–200 000]	<b>0.9</b> [0.8–1.1]	<b>90 000</b> [74 000–110 000]	<b>0.6</b> [0.5–0.8]	<b>0.5</b> [0.4–0.7]
CENTRAL ASIA	2001	<b>410 000</b> [340 000–490 000]	<b>210 000</b> [170 000–240 000]	<b>0.3</b> [0.2–0.3]	<b>7800</b> [6000–11 000]	<b>0.3</b> [0.2–0.3]	<b>0.2</b> [0.1–0.2]

		Adults and children living with HIV	Adults and children newly infected with HIV	Adult prevalence (%)	Adult and child deaths due to AIDS	Young people (15– 24) prevalence (%) Male Female	
WESTERN AND CENTRAL EUROPE	2010	<b>840 000</b> [770 000930 000]	<b>30 000</b> [22 000-39 000]	<b>0.2</b> [0.2–0.2]	<b>9900</b> [8900–11 000]	<b>0.1</b> [0.1–0.1]	<b>0.1</b> [<0.1–0.1]
	2001	<b>630 000</b> [580 000–690 000]	<b>30 000</b> [26 000–34 000]	<b>0.2</b> [0.2–0.2]	<b>10 000</b> [9500–11 000]	<b>0.1</b> [0.1–0.1]	<b>0.1</b> [0.1–0.1]
NORTH AMERICA	2010	1.3 million [1.0–1.9 million]	<b>58 000</b> [24 000–130 000]	<b>0.6</b> [0.5–0.9]	<b>20 000</b> [16 000–27 000]	<b>0.3</b> [0.2–0.6]	<b>0.2</b> [0.1–0.4]
	2001	980 000 [780 000–1.2 million]	<b>49 000</b> [34 000–70 000]	0.5 [0.4–0.7]	<b>19 000</b> [15 000-24 000]	0.3 [0.2-0.4]	<b>0.2</b> [0.1–0.3]

Regional estimates of adults and children newly infected with HIV, people living with HIV, and AIDSrelated deaths

		Adults and children living with HIV	Its and children Adults and children Adult prevalence (%)		Adult and child deaths due to AIDS	Young people (15– 24) prevalence (%)		
			with HIV			Male	Female	
TOTAL	2010	<b>34.0 million</b> [31.6–35.2 million]	<b>2.7 million</b> [2.4–2.9 million]	<b>0.8</b> [0.8–0.8]	1.8 million [1.6–1.9 million]	<b>0.3</b> [0.3–0.3]	<b>0.6</b> [0.5–0.6]	
	2001	28.6 million [26.7-30.9 million]	3.1 million [3.0-3.3 million]	<b>0.8</b> [0.7–0.8]	1.9 million [1.7-2.2 million]	<b>0.4</b> [0.4–0.4]	<b>0.8</b> [0.7–0.8]	



6

#### **Trends in women living with HIV**









### **New HIV infection trends**

The course of new HIV infections, compared to estimates if key changes had not happened





#### **GLOBAL HIV/AIDS RESPONSE**

Epidemic update and health sector progress towards Universal Access

Progress Report **2011** 







#### Number of people receiving antiretroviral therapy in low- and middleincome countries, by region, 2002–2010





# Scale-up of ART, number of AIDS deaths and new HIV infections in LMIC\*, 2001–2011



### 8 million on ART by end 2011 ...15 million is achievable !





# **ART scale-up: three success stories**





# Disparities in ART coverage between regions and populations



#### Proportion of eligible population receiving antiretroviral therapy in low- and middle-income countries at the end of 2010

Rapid increases in ART coverage are helping more countries achieve universal access to treatment, care and support.

20%-39%

Ma Source

		Algeria	Indonesia						
		Angola	Kazakhstan						
		Armenia	Lebanon	40%-	-59%				
		Azerbaijan	Liberia		<b>JJ</b> <sup>1</sup>				
		Bangladesh	Lithuania	Belarus	Malawi				
		Bhutan	Malaysia	Belize	Mali				
		Bolivia	Mauritania	Benin	Mozambique				
		Bulgaria	Mongolia	Burkina Faso	Oman				
		Burundi	Morocco	Cape Verde	Papua New Guinea				
		Cameroon	Myanmar	Congo	Peru				
0%-	-19%	CAR	Niger	El Salvador	Philippines				
•.•	- )	Chad	Nigeria	Eritrea	Senegal	60%-	-79%		
Afghanistan	Mauritius	China	Panama	Gabon	South Africa	•••••	1		
DR Congo	Nepal	Colombia	Poland	Guatemala	Suriname	Argentina	Mexico		80%
Djibouti	Pakistan	Côte d'Ivoire	Rep. of Moldova	Guinea	Тодо	Brazil	Paraguay		50/6
Egypt	Somalia	Eq Guinea	Russian Fed	Guinea- Bissau	Turkey	Costa Rica	Romania	Botswana	Guyana
Iran	Sudan	Fiji	Sao Tome and Principe	Haiti	Uganda	Dominican Rep	Swaziland	Cambodia	Namibia
Kyrgyzstan	Tajikistan	Gambia	Serbia	Honduras	UR Tanzania	Ecuador	Thailand	Chile	Nicaragua
Latvia	Tunisia	Ghana	Sierra Leone	Jamaica	Venezuela	Ethiopia	Uruguay	Comoros	Rwanda
Madagascar	Ukraine	Hungary	Sri Lanka	Lao PDR	Viet Nam	Georgia	Zambia	Croatia	Slovakia
Maldives		India	Uzbekistan	Lesotho	Zimbabwe	Kenya		Cuba	



# New infections, behaviour change and treatment coverage in Botswana



Source: Botswana AIDS indicator surveys; UNAIDS; WHO.



#### Condom use and HIV prevalence among sex workers in Cambodia

Percentage of sex workers using condoms and HIV prevalence among brothel-based sex workers in Cambodia

by length of time involved in sex work, 1998–2007.



- HIV prevalence among women working less than 1 year at brothel
- HIV prevalence among women working less than 2 years at brothel
- Percent of sex workers reporting condom use at last sex

Source: M Mahy, C Chhea, T Saliuk, O Varetska, R Lyerla (2010). A proxy measure for HIV incidence among populations at increased risk to HIV Vol 2(1):8, Journal of HIV/AIDS Surveillance and Epidemiology.

51

# Ecological aossociations and the difficulties of evidence for prevention

Principles and Practice of Sexually Transmitted Diseases Prevention and car

### Percentage of pregnant women who received an HIV test in the past 12 months in low- and middle-income countries by

#### region, 2005 and 2008–2010





#### Percentage of women and men who received an HIV test and test results in the 12 months preceding the survey in countries with repeat population surveys, 2003–2010





# More than half of pregnant women covered by ART in countries with a generalized epidemic, 2011

<25%	25–49%	50–74%	75–100%		
Angola Chad Congo Djibouti Eritrea Ethiopia Nigeria South Sudan	Benin Burkina Faso CAR Gabon Guinea Guinea-Bissau Papua New Guinea	Burundi Cameroon Côte d'Ivoire Kenya Lesotho Liberia Malawi Mozambique Rwanda Sierra Leone Togo Uganda UR Tanzania Zimbabwe	Botswana Ghana Haiti Namibia South Africa Swaziland		

Source: 2012 country progress reports (www.unaids.org/cpr) and UNAIDS estimates.



Estimated percent of pregnant women living with HIV who receive effective antiretroviral regimens, in 22 priority countries



*Note*: no estimate is available for Ethiopia

Source: UNAIDS, UNICEF and WHO, 2011.



# New HIV infections among children: Scenarios for 21 priority countries



•••• 90% coverage of highly effective antiretrovirals

•••• 90% ARV coverage; 50% reduction in incidence; no unmet need for family planning

*Note*: These 21 countries, plus India, comprise the 22 priority countries in the *Global Plan Towards the Elimination of New HIV infections Among Children and Keeping Their Mothers Alive*.



## Outline

#### HIV Prevention:

- Male circumcision
- Treatment as Prevention



## **HIV prevention through male circumcision**





#### Research: ecological studies HIV seroprevalence in 37 African cities and

proportion of males circumcised







## MC and HIV prevalence: geographic variation in Africa

Adapted from Halperin & Bailey, Lancet 1999; 354: 1813







## Randomised controlled trials of MC to reduce HIV infection completed



Source: 2006 Report on the global AIDS epidemic (UNAIDS, May 2006)

Rakai, Uganda Gray *et. al.* (2007) Lancet; 369: 657 – 66

Kisumu, Kenya Bailey *et. al.* (2007) Lancet; 369: 643 – 56

Orange Farm, South Africa Auvert *et. al.* (2005) PLoS Med; 2 (11): e298

> World Health Organization

### Completed Efficacy Trials of Interventions for Prevention of Sexual Transmission of HIV (by Oct 2011)

Intervention	Completed	Efficacious
Behavioral, social	8	0
Cervical barriers	1	0
Male circumcision (heterosexuals)	3	<b>3</b> (Orange Farm, Rakai, Kisumu – protective effect for males)
STI treatment	6	<b>1</b> (Mwanza)
HSV-2 suppression	3	0
PrEP (oral TDF± FTC - MSM, transgender, heterosexuals)	4	<b>3</b> (iPrEx, TDF-2, Partners PrEP)
ART for HIV+ partner (HIV heterosexual serodiscordant couples)	1	<b>1</b> (HTPN052)
<b>Microbicides</b> (Nonoxynol 9, C31G,Cellulose sulphate, PC-515, Buffer Gel, PRO 2000, TDF vaginal gel)	12	<b>1</b> (CAPRISA 004 - TDF vaginal gel)
HIV vaccines (rgp 120, M RK Ad5, RV 144)	4	<b>1</b> (Thai RV 144)
TOTAL	43	10

## **Evidence** summary

# Overall 60% reduction in risk



Weiss et al, AIDS. 2008;22(5):567-74





## Strategic use of antiretrovirals

## **Antiretroviral Treatment as HIV Prevention:**



## Geographical distribution of ART for prevention studies



Dark blue represents countries conducting ART in prevention research, light blue represents countrywide efforts (United States, Swaziland), red dots represent selected study sites within countries (some countries had too many sites to represent on this graphic)

Source: Granich et al 2011

65 Principles and Practice of Sexually Transmitted Diseases Prevention and Care



### **Rakai Study of viral load and HIV transmission**



## **Evidence from HPTN 052**

1763 HIV-discordant couples in 9 countries, CD4=250-550

Randomized to immediate or deferred treatment

Stopped for efficacy

67

39 HIV-ve partners were infected of which 29 were linked virologically to the infected partner

Of these 29 only 1 was in the immediate treatment group HR = 0.04 (95% CI: 0.01–0.27)

Also significant reduction in morbidity endpoints in treated individuals – HR for serious clinical endpoints = 0.59 (95% CI: 0.40-0.88)



## Balance of evidence favours earlier initiation of ART

### **Delayed ART**

- $\downarrow$  Drug toxicity
- ↓ Resistance
- Upfront costs Preservation of Tx options

### **Earlier ART**

- ↑ Clinical benefits (AIDS- and non-AIDS related)
- $\downarrow$  HIV and TB transmission
- **†** Potency, durability, tolerability
- ↑ Treatment sequencing options
  - Medium/long-term cost



# Relationship between transmitted resistance to NNRTI drugs and ART coverage in LMIC



69 Principles and Practice of Sexually Transmitted Diseases Prevention and Care



#### Going to Zero? The 2011 Investment Framework Combination prevention and treatment (new guidelines)

#### Number of new HIV infections





## Conclusions

- HIV epidemic stable and declining but with increasing in some geographical areas or populations
- Improved national response in LMIC
- MC as a tool in SSA for prevention
- Treatment as Prevention strategies
- New Comprehensive WHO guidelines in 2013 on the use of ARVs

